论文部分内容阅读
目的:探讨布地奈德混悬液联合复方异丙托溴铵雾化吸入治疗慢性阻塞性肺疾病急性加重期(AECOPD)的临床疗效。方法:选取我院在2012年1月至2014年1月收治的AECOPD患者60例,随机分为研究组和对照组,对照组给予常规治疗,研究组在常规治疗基础上加用布地奈德混悬液结合复方异丙托溴铵雾化吸入治疗,治疗7-10d后比较两组疗效。结果:研究组在治疗后咳嗽缓解时间、咯痰消失时间、喘息缓解时间以及湿啰音消失时间均明显优于对照组(P<0.05);研究组治疗总有效率为90.0%,明显大于对照组(P<0.05);两组均未见严重不良反应发生。结论:在常规治疗的基础上,加用布地奈德混悬液结合复方异丙托溴铵雾化吸入治疗AECOPD可明显纠正其缺氧和二氧化碳潴留症状,具有较好疗效和安全性。
Objective: To investigate the clinical efficacy of budesonide combined with ipratropium bromide in the treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods: Sixty patients with AECOPD admitted to our hospital from January 2012 to January 2014 were randomly divided into study group and control group. The control group received routine treatment. The study group was given budesonide mixed Suspension combined with compound ipratropium bromide inhalation therapy, after treatment for 7-10 days, the two groups were compared. Results: After treatment, the study group was significantly better than the control group in cough relief time, disappearance of expectoration, time to wheezing relief, and disappearance of wet rales (P <0.05). The total effective rate was 90.0% in the study group, which was significantly higher than that in the control group Group (P <0.05). No serious adverse reactions occurred in both groups. Conclusion: Based on routine treatment, the combination of budesonide suspension and compound ipratropium bromide inhalation for the treatment of AECOPD can obviously correct the symptoms of hypoxia and carbon dioxide retention, and has good curative effect and safety.